Skip to main content
. 2020 Jan 27;8:e8398. doi: 10.7717/peerj.8398

Table 1. Baseline characteristics of patients treated with resection or ablation before PSM.

Characteristics Resection (n = 250, %) Ablation (n = 171, %) P value
Age
Average 55.68 ± 10.64 56.58 ± 13.15 0.385
≤60 161(64.4) 103(60.2)
>60 89(35.6) 68(39.8)
Gender 0.285
Male 163(65.2) 120(70.2)
Female 87(34.8) 51(29.8)
Comorbidity 0.766
No 144(57.6) 96(56.1)
Yes 106(42.4) 75(43.9)
Primary tumor side 0.914
Left-side colorectum 197(78.8) 134(78.4)
Right-side colon 53(21.2) 37(21.6)
TNM stage
T stage 0.067
1–3 122(48.8) 68(39.8)
4 128(51.2) 103(60.2)
N stage 0.183
0 113(45.2) 64(37.4)
1 96(38.4) 69(40.4)
2 41(16.4) 38(22.2)
IVTTa 0.734
Positive 89(35.6) 51(29.8)
Negative 126(50.4) 78(45.6)
Differentiation (primary) 0.446
Poor 58(23.2) 35(20.5)
Moderate 181(72.4) 124(72.5)
Well 11(4.4) 12(7.0)
Metastases diameter (cm) 0.001
≤3 189(75.6) 152(88.9)
>3, ≤5 61(24.4) 19(11.1)
Metastases number 0.561
1 126(50.4) 88(51.5)
2 56(22.4) 45(26.3)
3 33(13.2) 16(9.3)
4–5 35(14.0) 22(12.9)
Metastases distribution 0.921
Unilobar 137(54.8) 95(55.6)
Multilobar (>1 lobe) 113(45.2) 76(44.4)
Preoperative chemotherapy 0.855
No 84(33.6) 56(32.7)
Yes 166(66.4) 115(67.3)
Postoperative chemotherapy <0.001
No 22(8.8) 42(24.6)
Yes 228(91.2) 129(75.4)
KRAS statusb 0.391
Wild type 71(28.4) 49(28.7)
Mutation type 42(16.8) 22(12.9)
CEA level (ng/ml) 0.899
≤5 111(44.4) 77(45.0)
>5 139(55.6) 94(55.0)
Timing of metastasis (months) 0.084
Synchronous (<12) 29(11.6) 30(17.5)
Metachronous (≥12) 221(88.4) 141(82.5)

Notes.

a

Data of 344 patients were available.

b

Data of 184 patients were available.

PSM
Propensity score matching
IVTT
Intravascular tumor thrombus